Publications

 


  • 118. The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy].

    Hoedemaeker RF, van der Kwast TH, Schröder FH., 2001

    Journal: Ned tijdschr Urol
    Reference: 9:3-9.

  • 117. Screening for prostate cancer: evidence and perspectives.

    Schröder FH, Wildhagen MF, and ERSPC study groop., 2001

    Journal: BJU
    Reference: 88:811-817.

    paper

  • 116. Prospective detection of clinically relevant prostate cancer in the prostate-specific antigen range 1 to 3.0 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience.

    Recker R, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R., 2001

    Journal: J Urol
    Reference: 166:851-855.

    paper

  • 115. Prostate-specific antigen density: Is there a role for this parameter when screening for prostate cancer?

    Lujan M, Paez A, Miravalles E, Berenguer A., 2001

    Journal: Prostate Cancer and prostatic diseases
    Reference: 4:146-9.

    paper

  • 114. Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model.

    Vis AN, Hoedemaeker RF, Kwast TH van der, Schröder FH., 2001

    Journal: The Prostate
    Reference: 46:154-162.

    paper

  • 113. Management of a prostate cancer research program in the City of Antwerp

    Standaert B, Alwan A, Dourcy-Belle-Rose B, Nelen V, Denis L., 2001

    Journal: Arch Public Health
    Reference: 59:167-80

    paper

  • 112. Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges.

    Schröder FH., 2001

    Journal: Eur Urol
    Reference: Apr;39 Suppl 4:49-53.

  • 111. Prostate-specific antigen and other prostate cancer markers.

    Stenman UH, Finne P, Zhang WM, Leinonen J., 2000

    Journal: Urology
    Reference: 56:893-898.

    paper

  • 110. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry.

    Spapen SJJC, Damhuis RAM, Kirkels WJ., 2000

    Journal: BJUI
    Reference: 85:474-480.

    paper

  • 109. Why do men refuse or attend population-based screening for prostate cancer?

    Nijs HGT, Essink-Bot ML, De Koning HJ, Kirkels WJ, Schröder FH., 2000

    Journal: Journal of Public Health Medicine
    Reference: 22(3):312-316.

    paper

  • 108. Staging Prostate Cancer.

    Hoedemaeker RF, Vis AN, van der Kwast ThH., 2000

    Journal: Microscopy Research and Technique
    Reference: 51 (5):423-429.

    paper

  • 107. Prostate Cancer Screening.

    Alexander FE., 2000

    Journal: Microscopy Research and Technique
    Reference: 51 (5):419-422.

    paper

  • 106. Introduction: Current topics in Prostate Cancer Research.

    Hoedemaeker RF., 2000

    Journal: Microscopy Research and Technique
    Reference: 51 (5):413-414.

    paper

  • 105. Data of Spanish contribution to the European Randomized Study of Screening for Prostate Cancer (ERSPC).

    Luján M, Paez A, Llanes L, Romero I, Moreno A, Berenguer A., 2000

    Journal: Brazilian Journal of Urology
    Reference: 26(5):510-515.

    paper

  • 104. Characteristics of prostatic cancer undetected in the first assessment of a screening program. Quality control. (Article in Spanish).

    Lújan Galan M, Paez Borda A, Llanes Gonzalez L, Fernandez Gonzalez I, Moreno Santurino A, Berenguer Sanchez A., 2000

    Journal: Arch Esp Urol
    Reference: 53(10):900-4.

    paper

  • 103. Rasgos diferenciales del cáncer de próstata procedente de un programa de detección precoz frente al detectado en una consulta de urología..

    Luján Galán M, Páez Borda A, Llanes González L, Gómez de Vicente JM, Romero Cajigal I, Berenguer Sánchez A., 2000

    Journal: Actas.Urol.Esp
    Reference: 24(8):640-643.

    paper

  • 102. Significado clínico de la neoplasia intraepitelial prostática.

    Luján Galán M, Páez Borda A, Romero Cajigal I, Gómez de Vicente JM, Berenguer Sánchez A., 2000

    Journal: Arch. Esp. Urol.
    Reference: 53(3):227-9.

    paper

  • 101. Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging.

    Llanes L, Páez A, Ferruelo A, Luján M, Romero I, Berenguer A., 2000

    Journal: BJUI
    Reference: 86:1023-1027.

    paper

  • 100. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network.

    Finne P, Finne R, Auvinen A, Juusela H, Aro J, Maattanen L, Hakama M, Rannikko S, Tammela TL, Stenman U., 2000

    Journal: Urology
    Reference: 56(3):418-22.

    paper

  • 99. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen..

    Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S, Tammela T, Seppala M, Hakama M, Stenman UH., 2000

    Journal: J Clin Endocrinol Metab
    Reference: 85(8):2744-7.

    paper

  • 98. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.

    Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, van der Maas PJ, Schröder FH., 2000

    Journal: J Urol.
    Reference: 164(4):1216-20.

    paper

  • 97. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.

    Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G., 2000

    Journal: BJUI
    Reference: 85: 1078-1084

    paper

  • 96. Histo-pathological prostate cancer characteristics at radical prostatectomy after population-based screening.

    Hoedemaeker RF, Rietbergen JBW, Kranse R, Schröder FH, van der Kwast TH., 2000

    Journal: Journal of Urology
    Reference: 164: 411-415, August 2000.

    paper

  • 95. Screening and Early Detection of Prostate Cancer.

    Schröder FH, Alexander FE, Bangma ChH, Hugosson J, Smith DS., 2000

    Journal: The Prostate
    Reference: 44:255-263

    paper

  • 94. PSA – A surrogate endpoint for screening new agents against prostate cancer?

    Schröder FH, Kranse R, Barbet N, Hop WCJ, Kandra A, Lassus M., 2000

    Journal: The Prostate
    Reference: 42(2):107-15

    paper

  • 93. Prostate cancer detection at low prostate specific antigen.

    Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R., 2000

    Journal: J of Urol
    Reference: 163 (3):806-12.

    paper

  • 92. Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections.

    Vis AN, Kranse R, Nigg AL, van der Kwast ThH., 2000

    Journal: Am. J. Clin. Pathol.
    Reference: 113 (3):369-373.

    paper

  • 91. Detection of Prostate Cancer: A Comparative Study of the Diagnostic Efficacy of Sextant Transrectal versus Sextant Transperineal Biopsy.

    Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast Th.H.., 2000

    Journal: Urology
    Reference: 56(4):617-21.

    paper

  • 90. Prognostic value of cell cycle proteins p27kip1, MIB-1, and the cell-adhesion protein CD44s in surgically treated patients with prostate cancer.

    Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, van der Kwast, Th.H., 2000

    Journal: J Urol
    Reference: 164(6):2156-2161.

    paper

  • 89. Reihenuntersuchungen zur Entdeckung von Prostatakarzinomen.

    Bangma CH., 2000

    Journal: Der Urologe (A)
    Reference: 39(4):334-340. Zum thema: 10 Jahre PSA.

  • 88. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction.

    Boer R, Schröder FH., 1999

    Journal: The Prostate
    Reference: 40: 130-131.

  • 87. New Developments in the Standardization of Total Prostate-Specific Antigen.

    Blijenberg BG, Storm BN, van Zelst BD, Boeken Kruger AE, Schröder FH., 1999

    Journal: Clinical Biochemistry
    Reference: 32(8):627-634.

  • 86. The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update.

    Schröder FH, Kranse R, Rietbergen JBW, Hoedemaeker RF, Kirkels WJ and members of the ERSPC, section Rotterdam., 1999

    Journal: Eur Urol
    Reference: 35:539-543.

    paper

  • 85. PSA variation in patients without clinically evident prostate cancer.

    Lujan M., Paez A., Sanchez E., Herrero A., Martin E., Berenguer A., 1999

    Journal: J of Urol
    Reference: Oct 162(4):1311- 1313.

    paper

  • 84. Resultado de un programa de screening para el cáncer de próstata.

    Martin Oses E., Lujan Galan M., Sanchez Sanchez E., Herrero Payo A., Paez Borda A., Berenguer Sanchez A., 1999

    Journal: Actas Urol Esp
    Reference: 23(4):287-295.

    paper

  • 83. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.

    Hoedemaeker RF, Kranse R, Rietbergen JBW, Boeken Kruger AE, Schröder FH, Van der Kwast ThH., 1999

    Journal: Cancer
    Reference: 85(1)145-152.

    paper

  • 82. Advanced disease in prostate cancer, course, care and cost implications.

    Beemsterboer PMM, De Koning HJ, Birnie E, Van der Maas PJ, Schröder FH., 1999

    Journal: The Prostate
    Reference: 40:97-104.

    paper

  • 81. Predictors for Biopsy Outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).

    Kranse R, Beemsterboer PMM, Rietbergen JBW, Habbema D, Hugosson J, Schröder FH., 1999

    Journal: The Prostate
    Reference: 39:316-322.

    paper

  • 80. European Randomized Study of Prostate Cancer screening: first-year results of the Finnish trial.

    Määttänen L, Auvinen A, Stenman U-H, Ranniko S, Tammela T, Aro J, Hakama M., 1999

    Journal: B J of Urol
    Reference: 79(7/8):1210-1214.

    paper

  • 79. Final results of a screening campaign for prostate cancer.

    Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A., 1999

    Journal: European Urol
    Reference: 35:26-31.

  • 78. On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparations.

    Blijenberg BG, Storm BN, Boeken Kruger AE, Schröder FH., 1999

    Journal: Clin Chem Lab Med
    Reference: 37 (5): 545-552.

  • 77. Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer Rotterdam).

    Beemsterboer PMM, Kranse R, Koning HJ de, Habbema JDF, Schröder FH., 1999

    Journal: Int J Cancer
    Reference: 84 (4): 437-441.

    paper

  • 76. Lest we abandon digital rectal examination as a screening test for prostate cancer.

    Schröder FH., 1999

    Journal: J Natl Cancer Inst
    Reference: 91 (15): 1331-1332.

  • 75. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancers in a population-based screening study.

    Rietbergen JBW, Hoedemaeker RF, Boeken Kruger AE, Kirkels WJ, Schröder FH., 1999

    Journal: J Urol
    Reference: 161 (4): 1192-1198.

    paper

  • 74. Rationale for randomised trials of prostate cancer screening.

    The International Prostate Screening Trial Evaluation Group (IPSTEG)., 1999

    Journal: Eur J Cancer
    Reference: 35 (2): 262-271.

    paper

  • 73. Screening for prostate cancer.

    Bangma CH., 1999

    Journal: Cancer Topics
    Reference: 11 (1) July/August: 10-12.

  • 72. PSA screening for prostate cancer: The current controversy.

    Koning de HJ, Schröder FH., 1998

    Journal: Annals of Oncology
    Reference: 9:1293-1296.

  • 71. Short-term effects of population-based screening for prostate cancer on Health-Related Quality of Life.

    Essink-Bot ML, De Koning HJ, Nijs HGT, Kirkels WJ, Van der Maas PJ, Schröder FH., 1998

    Journal: JNCI
    Reference: 12:925-931.

    paper

  • 70. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence screening pilot study.

    Zappa M, Ciatto S, Bonardi R, Mazzotta A., 1998

    Journal: Annals of Oncology
    Reference: 9(12):1297-1301.

    paper

  • 69. Analytical issues on prostate-specific antigen in relation to prostate cancer screening.

    Blijenberg BG, Roobol M, Schröder FH., 1998

    Journal: Clin Biochemistry
    Reference: 31(8):633-639.

    paper

← PreviousNext →